Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62011TN0605

    Case T-605/11: Action brought on 29 November 2011 — Novartis v OHIM — Organic (BIOCERT)

    OJ C 32, 4.2.2012, p. 31–32 (BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    4.2.2012   

    EN

    Official Journal of the European Union

    C 32/31


    Action brought on 29 November 2011 — Novartis v OHIM — Organic (BIOCERT)

    (Case T-605/11)

    2012/C 32/65

    Language in which the application was lodged: English

    Parties

    Applicant: Novartis AG (Basel, Switzerland) (represented by: M. Douglas, lawyer)

    Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

    Other party to the proceedings before the Board of Appeal: Dr. Organic Ltd (Swansea, United Kingdom)

    Form of order sought

    Annul the decision of the Fourth Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 28 September 2011 in case R 1030/2010-4; and

    Order the defendant to bear the costs of the proceedings.

    Pleas in law and main arguments

    Applicant for a Community trade mark: The other party to the proceedings before the Board of Appeal

    Community trade mark concerned: The word mark ‘BIOCERT’, for goods and services in classes 3, 4, 5, 29, 30, 31, 32, 35 and 44 — Community trade mark application No 7134984

    Proprietor of the mark or sign cited in the opposition proceedings: The applicant

    Mark or sign cited in opposition: Austrian trade mark registration No 136273 of the word mark ‘BIOCEF’, for goods in class 5

    Decision of the Opposition Division: Rejected the opposition in its entirety

    Decision of the Board of Appeal: Dismissed the appeal

    Pleas in law: Infringement of Articles 8(1)(b) and 76(1) of Council Regulation No 207/2009, as the Board of Appeal: (i) misinterpreted general principles laid down by the European courts and wrongly concluded that there is no likelihood of confusion between ‘BIOCEF’ and ‘BIOCERT’; and (ii) wrongly based its decision on facts which have not been forwarded by the parties of the proceedings.


    Top